13 min listen
ANNEXA-1: Andexanet Alfa Associated with Harm in DOAC Reversal
FromREBEL Cast
ratings:
Length:
20 minutes
Released:
May 23, 2024
Format:
Podcast episode
Description
Background: In May of 2018, Andexanet alfa gained accelerated approval by the FDA for the reversal direct oral anticoagulants (DOACs) despite a lack of robust evidence for use. The 2022 AHA/ASA guidelines give the drug a level 2A recommendation and recommend it over the use of 4F-PCC (Greenberg 2022). FDA approval alongside guideline endorsement has ... Read more
The post ANNEXA-1: Andexanet Alfa Associated with Harm in DOAC Reversal appeared first on REBEL EM - Emergency Medicine Blog.
The post ANNEXA-1: Andexanet Alfa Associated with Harm in DOAC Reversal appeared first on REBEL EM - Emergency Medicine Blog.
Released:
May 23, 2024
Format:
Podcast episode
Titles in the series (49)
REBEL Core Cast 93.0 – Lithium Toxicity: Take Home Points Lithium toxicity comes in a three flavors: acute, chronic and acute on chronic. Each form will have a different presentation as well as management. Lithium levels are often unreliable in terms of guiding management and must be taken in... by REBEL Cast